The Suppression

MODULE 5 PREVIEW PACK, The Suppression
For NotebookLM: generate a 12-15 minute preview podcast.
Format: Two hosts tell the story of the collision, the clinical tradition, the counterculture, the CIA, the scheduling. Narrative, not lecture.

---

THE CLINICAL PROGRAM

From 1947, when the manufacturer first distributed LSD under a trade name, to the Controlled Substances Act of 1970, the psychedelic research program produced:

Over 1,000 published scientific papers
Approximately 40,000 patients treated with LSD-assisted therapy
Clinical programs at institutions in the US, UK, Canada, and Europe
Documented success rates in alcoholism treatment (Hoffer-Osmond at Weyburn: ~50% lasting sobriety), end-of-life anxiety, neurotic disorders, and treatment-resistant depression

The program was not fringe science. It operated at respected psychiatric institutions. It published in peer-reviewed journals. It held international conferences. By 1965, it was approaching the stage at which regulatory submissions might have become possible.

THE THREE FORCES THAT DESTROYED IT

Force 1: The CIA. Operation MK-Ultra (1953-1973) used LSD as a potential tool for interrogation and behavioral control. The CIA purchased the world's entire LSD supply from the manufacturer in 1953. It dosed unwitting subjects in safe houses. It produced no useful intelligence. It produced at least one death (Frank Olson, 1953). The program, when revealed by the Church Committee in 1975, permanently tainted LSD's public image.

Force 2: Timothy Leary. The Harvard Psilocybin Project's early work was careful and promising. Leary's pivot to mass public advocacy..."Turn on, tune in, drop out", associated LSD with countercultural rebellion against the social order, providing the political justification for suppression.

Force 3: The Nixon Administration. John Ehrlichman, Nixon's domestic policy adviser, stated in a 1994 interview (published Harper's, 2016): "We knew we couldn't make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities." The account rests on Baum's notes alone, and Ehrlichman's family and several former Nixon aides dispute it. The drug war was explicitly a tool of political suppression.

October 6, 1968: The Staggers-Dodd Act made LSD possession a federal misdemeanor. The research stopped.

THE RESUMPTION

The research resumed approximately fifty years later. Johns Hopkins' 2016 psilocybin study for end-of-life anxiety. NYU's 2016 psilocybin study for alcohol use disorder. Industry Phase 3 trials for psilocybin in treatment-resistant depression, reporting in 2025 and 2026.

The research program that was interrupted in 1968 is currently approaching regulatory approval, fifty-five years after it was stopped.

THREE THINGS TO WATCH FOR

1. The distinction between the research being stopped because it failed versus being stopped because it was politically inconvenient. These are different events with different implications.

2. The Leary question. Stevens is careful not to make Leary a simple villain. What is the right framing of his role?

3. The FDA's August 2024 rejection of MDMA-assisted therapy. The Phase 3 efficacy data was significant. The rejection was on methodological grounds. Is this the same pattern as 1968, or a different situation?

MODULE 5 EVIDENCE PACK, The Clinical Record Then and Now
For NotebookLM: generate a 15-18 minute evidence episode.
Format: Two hosts compare the pre-prohibition clinical evidence with the post-resumption clinical evidence. What do we now know that was known in 1968? What is genuinely new?

---

WHAT THE 1947-1968 PROGRAM SHOWED

Alcoholism (Hoffer, Osmond and colleagues, Saskatchewan, 1950s):
uncontrolled reports that roughly half of treated patients improved or stopped drinking. A 2012 meta-analysis by Krebs and Johansen of six randomized controlled trials from the 1960s-70s found a statistically significant positive effect on alcohol misuse, with effects lasting 6-12 months. The result was real.

End-of-life anxiety (Pahnke, Maryland Psychiatric Research Center, 1960s):
LSD-assisted therapy significantly reduced death anxiety in terminal cancer patients. The mechanism identified: mystical experience quality correlated with anxiety reduction.

The clinical principle established: the quality of the experience, whether it reaches the threshold of genuine transformative encounter, predicts the therapeutic outcome more than drug dose alone.

WHAT THE RESUMPTION CONFIRMED

The Griffiths 2016 Johns Hopkins study: psilocybin for end-of-life anxiety in cancer patients. 80% showed clinically significant improvement at 6 months from a single session. The effect size was the largest reported in any psychological treatment study for this indication.

The 2022 Bogenschutz NYU RCT: psilocybin for alcohol use disorder. Significantly better outcomes than placebo, consistent with the Hoffer-Osmond result reproduced 60 years later with better methodology and a different compound.

The first (June 2025) and second (February 2026) Phase 3 trials: psilocybin for treatment-resistant depression. Both met primary endpoints. -3.6 to -3.8 MADRS points at Week 6, p<0.001. 25% of high-dose participants showed clinically meaningful response through 26 weeks.

THE MDMA SITUATION

The sponsor (formerly MAPS Public Benefit Corporation) submitted an NDA for MDMA-assisted therapy for PTSD in 2024. The FDA advisory committee voted 10-1 against approval in June 2024. The FDA issued a Complete Response Letter in August 2024 declining to approve.

The Phase 3 data: 67-71% of PTSD patients who received MDMA-assisted therapy no longer met diagnostic criteria at follow-up, versus approximately 32% in the placebo arm.

The FDA's concerns: the trials could not adequately blind participants to whether they received active MDMA or placebo; therapist expectancy bias was not adequately controlled; adverse events (cardiac, hypertensive) were inadequately characterized.

The FDA requested an additional Phase 3 trial with improved design.

This is not the same as 1968. The 1968 scheduling was not a regulatory rejection of a specific trial, it was a political prohibition of the entire research program. The 2024 MDMA rejection is a methodological critique of a specific trial. Whether the methodological critique is legitimate or uses methodological concerns as cover for regulatory caution is debated.

THE WHO CRITICAL REVIEWS

WHO ECDD Critical Review of LSD (2019) [Source not found; under review]: found no evidence supporting LSD's current international scheduling level. No recommendation was implemented.

WHO ECDD Critical Review of Cannabis (2019): recommended rescheduling. The US DOJ proposed rescheduling from Schedule I to Schedule III in May 2024. The process remains incomplete as of June 2026.

The pattern: scientific review bodies find the scheduling scientifically unjustified. The political process of changing it proceeds slowly, partially, and incompletely.